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Schistosomiasis is a debilitating parasitic disease which
affects 200 million people, causing lifethreatening
complications in 10% of the patients. We are investigating
several proteins interfering in critical steps of schistosome
development in order to look for a good candidate as a vaccine
and/or drug target. We cloned, expressed, purified two of these
candidates: a stathmin-like protein from the human blood fluke
Schistosoma Mansoni (SmSLP) and a cyclophilin-like protein
fromHaemonchus Contortus, the equivalent of S.m. in bovines.
Both proteins were segregated in inclusion bodies, hence their
purification involved also a refolding step. Stathmin is a
ubiquitous 17 kDa cytosolic phosphoprotein proposed to play
an general role in the cell growth and differentation through its
capacity to regulate microtubule assembly dynamics. It works
by sequestering tubulin in a complex made by two tubulin
heterodymers per stathmin molecule. SmSLP[1] is first
synthesized at high levels in the intermediate molluscan host
and completely disappeares 48h after the penetration into the
mammalian host.
Cyclophilin[2] is a cytosolic protein with a high affinity for
the immunosuppressive drug cyclosporin A. Cyclophilins are
known to possess enzymatic activity in the form of
peptidyl-prolyl cis-trans isomerase catalysis, a reaction thought
to be involved in the late stages of protein folding. Moreover
this cyclophilin-like protein has been shown to bind RNA in the
nucleolus, therefore a putative role in transcription/translation
regulation is inferred. We succeeded in the purification and
refolding of both proteins. We have set up crystallization trials
of both proteins and actually we are trying to optimize their
crystallizations conditions.
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Lysostaphin is under development as a protein drug to
eradicate nasal Staphylococcus aureus infections. In spite of the
strong practical interest in lysostaphin-type enzymes, no
structure of any lysostaphin-type enzyme was available prior to
our work. We have recently solved the structure of LytM, the
first structure of a metallopeptidase of this family. The structure
generated several surprises: Firstly, and contrary to the prior
literature on the enzyme, it showed that full length LytM is a
latent enzyme, most likely the proform of the enzyme, a finding
that could be confirmed biochemically. Secondly, and more
importantly, it showed that sequence based assumptions about
the architecture of the active site of the enzyme have to be
revised. Finally, the structure showed an unexpected similarity
between the active sites of lysostaphin-type peptidases of a large
group of peptidases with specificity for the peptidoglycan
building block D-Ala-D-Ala. As a similar arrangement of
residues is also present in the N-domain of sonic hedgehog, a
peptidase without known substrate so far, we propose for this
group of enzymes the term "LAS
(lysostaphin/D-Ala-D-Ala/sonic hedgehog)" enzymes
according to the initials of three main families.
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